Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: J Mol Cell Cardiol. 2011 Mar 29;51(1):24–32. doi: 10.1016/j.yjmcc.2011.03.003

Figure 6. A-769662 pre-treatment activates AMPK and reduces myocardial infarct size in vivo.

Figure 6

(A) Anesthetized WT and AMPK KD mice were treated with A-769662 (6 mg/kg IP) or vehicle, and hearts were excised after 20 min. Heart homogenates were immunoblotted for p-AMPK (Thr172), AMPKα, p-ACC (Ser79), and ACC. Representative blots and quantification of the ratios of phosphorylated to total protein content are shown (n=4-6/group). (B and C) Anesthetized WT and AMPK KD mice were treated with A-769662 (6 mg/kg IP) or vehicle 30 min prior to left coronary artery ligation (20 min) and reperfusion (4 hours). Representative dual stained heart sections and bar graphs quantifying the ratio of infarcted area (INF) to the area at risk (AAR) and the ratio of AAR to total left ventricular area (LV) are shown (n=5-7/group). (D) Additional hearts were fixed and apoptotic nuclei in the ischemic-reperfused region were identified by TUNEL staining (original magnification, x40) (n=4/group). White bar, vehicle. Black bar, A-769662. Values are expressed as mean + SEM. *P<0.05.